Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
L Cai, Y Li, J Tan, L Xu, Y Li - Journal of hematology & oncology, 2023 - Springer
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials
X Chu, W Tian, Z Wang, J Zhang, R Zhou - Molecular cancer, 2023 - Springer
Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary
cancer treatment modality, offering long-lasting responses and survival benefits for a …
cancer treatment modality, offering long-lasting responses and survival benefits for a …
Advances in single-cell RNA sequencing and its applications in cancer research
D Huang, N Ma, X Li, Y Gou, Y Duan, B Liu… - Journal of hematology & …, 2023 - Springer
Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …
functional capabilities during the transition from a normal to a neoplastic state. Powerful …
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion
Chimeric antigen receptor (CAR) T cells have not induced meaningful clinical responses in
solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during …
solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during …
Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction
T cells engineered to express chimeric antigen receptors (CARs) targeting CD19 have
demonstrated impressive activity against relapsed or refractory B-cell cancers yet fail to …
demonstrated impressive activity against relapsed or refractory B-cell cancers yet fail to …
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
Summary LAG-3, TIM-3, and TIGIT comprise the next generation of immune checkpoint
receptors being harnessed in the clinic. Although initially studied for their roles in restraining …
receptors being harnessed in the clinic. Although initially studied for their roles in restraining …
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
Background Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene
autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and …
autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and …
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies,
but factors influencing the persistence of functional CAR+ T cells, such as product …
but factors influencing the persistence of functional CAR+ T cells, such as product …
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
T Lei, Y Wang, Y Zhang, Y Yang, J Cao, J Huang… - Leukemia, 2024 - nature.com
Abstract Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune
therapy. However, challenges remain including increasing efficacy, reducing adverse events …
therapy. However, challenges remain including increasing efficacy, reducing adverse events …
Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T-cell receptor lineages
TL Wilson, H Kim, CH Chou, D Langfitt, RC Mettelman… - Cancer discovery, 2022 - AACR
Current chimeric antigen receptor-modified (CAR) T-cell products are evaluated in bulk,
without assessing functional heterogeneity. We therefore generated a comprehensive single …
without assessing functional heterogeneity. We therefore generated a comprehensive single …